Department of Public Health, University Hospital of Nice, Nice, France; Université Côte d'Azur, CHU Nice, Nice, France.
Department of Public Health, University Hospital of Nice, Nice, France; CoBTeK Lab, Université Côte d'Azur, Nice, France.
Clin Microbiol Infect. 2022 Jan;28(1):114-123. doi: 10.1016/j.cmi.2021.09.010. Epub 2021 Sep 16.
Initial studies of individuals with coronavirus disease 2019 (COVID-19) revealed that obesity, diabetes and hypertension were associated with severe outcomes. Subsequently, some authors showed that the risk could vary according to age, gender, co-morbidities and medical history. In a nationwide retrospective cohort, we studied the association between these co-morbidities and patients' requirement for invasive mechanical ventilation (IMV) or their death.
All French adult inpatients with COVID-19 admitted during the first epidemic wave (February to September 2020) were included. When patients were diagnosed with obesity, diabetes or hypertension for the first time in 2020, these conditions were considered as incident co-morbidities, otherwise they were considered prevalent. We compared outcomes of IMV and in-hospital death according to obesity, diabetes and hypertension, taking age, gender and Charlson's co-morbidity index score (CCIS) into account.
A total of 134 209 adult inpatients with COVID-19 were included, half of them had hypertension (n = 66 613, 49.6%), one in four were diabetic (n = 32 209, 24.0%), and one in four were obese (n = 32 070, 23.9%). Among this cohort, IMV was required for 13 596 inpatients, and 19 969 patients died. IMV and death were more frequent in male patients (adjusted oods ratio (aOR) 2.0, 95% CI 1.9-2.1 and aOR 1.5, 95% CI 1.4-1.5, respectively), IMV in patients with co-morbidities (aOR 2.1, 95% CI 2.0-2.2 for CCIS = 2 and aOR 3.0, 95% CI 2.8-3.1 for CCIS ≥5), and death in patients aged 80 or above (aOR 17.0, 95% CI 15.5-18.6). Adjusted on age, gender and CCIS, death was more frequent among inpatients with obesity (aOR 1.2, 95% CI 1.1-1.2) and diabetes (aOR 1.2, 95% CI 1.1-1.2). IMV was more frequently necessary for inpatients with obesity (aOR 1.9, 95% CI 1.8-2.0), diabetes (aOR 1.4, 95% CI 1.3-1.4) and hypertension (aOR 1.7, 95% CI 1.6-1.8). Comparatively, IMV was more often required for patients with the following incident co-morbidities: obesity (aOR 3.5, 95% CI 3.3-3.7), diabetes (aOR 2.0, 95% CI 1.8-2.1) and hypertension (aOR 2.5, 95% CI 2.4-2.6).
Among 134 209 inpatients with COVID-19, mortality was more frequent among patients with obesity and diabetes. IMV was more frequently necessary for inpatients with obesity, diabetes and hypertension. Patients for whom these were incident co-morbidities were particularly at risk. Specific medical monitoring and vaccination should be priorities for patients with these co-morbidities.
最初对 2019 年冠状病毒病(COVID-19)患者的研究表明,肥胖症、糖尿病和高血压与严重后果相关。随后,一些作者表明,这种风险可能因年龄、性别、合并症和病史而有所不同。在一项全国性回顾性队列研究中,我们研究了这些合并症与患者需要接受有创机械通气(IMV)或死亡之间的关系。
纳入了在 2020 年第一波疫情(2 月至 9 月)期间因 COVID-19 入院的所有法国成年住院患者。当患者在 2020 年首次被诊断为肥胖症、糖尿病或高血压时,这些情况被视为新发合并症,否则则被视为已存在的合并症。我们考虑了年龄、性别和 Charlson 合并症指数评分(CCIS),比较了肥胖症、糖尿病和高血压与 IMV 和院内死亡的结果。
共纳入了 134209 名成年 COVID-19 住院患者,其中一半患有高血压(n=66613,49.6%),四分之一患有糖尿病(n=32209,24.0%),四分之一患有肥胖症(n=32070,23.9%)。在该队列中,有 13596 名住院患者需要接受 IMV,有 19969 名患者死亡。男性患者(调整后的优势比[aOR]2.0,95%置信区间[CI]2.0-2.1 和 aOR 1.5,95%CI 1.4-1.5)、合并症患者(CCIS=2 时 aOR 2.1,95%CI 2.0-2.2 和 CCIS≥5 时 aOR 3.0,95%CI 2.8-3.1)和 80 岁或以上的患者(aOR 17.0,95%CI 15.5-18.6)的 IMV 和死亡更为常见。在调整了年龄、性别和 CCIS 后,肥胖症(aOR 1.2,95%CI 1.1-1.2)和糖尿病(aOR 1.2,95%CI 1.1-1.2)患者的死亡率更高。肥胖症(aOR 1.9,95%CI 1.8-2.0)、糖尿病(aOR 1.4,95%CI 1.3-1.4)和高血压(aOR 1.7,95%CI 1.6-1.8)患者更频繁地需要接受 IMV。相比之下,肥胖症(aOR 3.5,95%CI 3.3-3.7)、糖尿病(aOR 2.0,95%CI 1.8-2.1)和高血压(aOR 2.5,95%CI 2.4-2.6)新发合并症患者更频繁地需要接受 IMV。
在 134209 名 COVID-19 住院患者中,肥胖症和糖尿病患者的死亡率更高。肥胖症、糖尿病和高血压患者更需要接受 IMV。新发这些合并症的患者风险特别高。应优先为这些合并症患者提供特定的医疗监测和疫苗接种。